For a lot of people managing moderate to severe plaque psoriasis, treatment means needles: an injection every few weeks, a cold pack, a schedule to keep. It’s effective, but it’s not exactly convenient. Now there’s early data on an oral option that could eventually offer a way around that, the same way ICOTYDE recently did for another corner of psoriasis treatment.
As reported by Dermatology Times, the drug, called socrodeucitinib, is a once-daily pill that targets TYK2, a protein involved in the same inflammatory signaling that today’s injectable biologics work to calm, minus the shot. In a phase 2 trial of adults with moderate to severe plaque psoriasis, it just met its primary goal.
What the Study Showed
Researchers split 125 adults into three groups, giving them either a 6 milligram dose, a 12 milligram dose or a placebo, once a day for 12 weeks. The higher dose was the clear standout. By week 12, nearly three-quarters of patients on 12 milligrams saw a 75 percent reduction in their psoriasis, known as PASI 75, compared with fewer than 8 percent of those on placebo. Almost half saw major clearance, a 90 percent reduction in symptoms, and about 1 in 9 saw their skin clear completely, something none of the placebo patients experienced. Quality of life scores improved right along with the skin.
The change didn’t take long to show up, either. Patients started seeing improvement within the first two weeks, and by week 4, many already had the kind of clearance the trial was measuring for at its 12-week finish line.
Safety So Far
Side effects were more common with the drug than with placebo, though researchers described most as mild to moderate. The most frequent was an upper respiratory infection, which became more common at the higher dose. A few patients also reported fever or minor changes in heart rhythm. Bloodwork looked clean across the board, with no concerning trends in liver, kidney or other lab values, and serious side effects were rare.
What This Means for You
This is still phase 2 data, so there’s a way to go. Researchers have chosen the 12 milligram dose to carry into phase 3 trials, the larger, longer studies that will need to confirm these results before socrodeucitinib could become available to patients. It’s also a good reminder that not every psoriasis treatment works the same way for every patient, which is exactly why having more options in development matters. For now, this is a hopeful early signal, not something to bring up at your next dermatologist appointment just yet.
